New Novartis Fabhalta® (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN)
GlobeNewswire
· APPLAUSE-IgAN is first and only Phase III study to demonstrate significant proteinuria reduction by targeting the complement..